| 何娟,郑倩,曹练,等.赖氨肌醇维生素 B12对特发性身材矮小症病儿骨龄年龄差及血清摄食抑制因子水平的影响[J].安徽医药,2026,30(6):1236-1241. |
| 赖氨肌醇维生素 B12对特发性身材矮小症病儿骨龄年龄差及血清摄食抑制因子水平的影响 |
| Effects of lysine, inositol and vitamin B12 on the difference between bone age and chronological age and serum nesfatin-1 level in children with idiopathic short stature |
| |
| DOI：10.3969/j.issn.1009-6469.2026.06.035 |
| 中文关键词: 特发性身材矮小症 赖氨肌醇维生素 B12 骨龄年龄差 摄食抑制因子 胰岛素样生长因子 -1 |
| 英文关键词: Idiopathic short stature Lysine inositol and vitamin B12 Difference between bone age and chronological age Nesfa. tin-1 Insulin-like growth factor-1 |
| 基金项目:河北省医学科学研究课题计划( 20231509) |
|
| 摘要点击次数: 50 |
| 全文下载次数: 10 |
| 中文摘要: |
| 目的探究赖氨肌醇维生素 B12对特发性身材矮小症( ISS)病儿骨龄年龄差及血清摄食抑制因子( nesfatin-1)水平的影响。方法前瞻性选择河北大学附属医院 2021年 2月至 2022年 6月收治的 ISS病儿 95例为研究对象，采用随机数字表法分为复方组( 48例)和重组人生长激素( rhGH)组( 47例)。 rhGH组予以 rhGH治疗，复方组在其基础上予以赖氨肌醇维生素 B12口服溶液治疗。比较两组骨龄年龄差、相关生长因子水平及不良反应发生率。结果治疗后两组身高、生长速率、骨龄高于治疗前，骨龄年龄差低于治疗前( P<0.05)。治疗后，与 rhGH组相比，复方组身高、生长速率、骨龄增加，骨龄年龄差［(0.07±0.02)岁比( 0.45±0.11)岁］减少( P<0.05)。与治疗前相比，治疗后两组病儿血清胰岛素样生长因子 -1(IGF-1)、胰岛素样生长因子结合蛋白( IGFBP3)、高密度脂蛋白胆固醇( HDL-C)、空腹血糖( FPG)、胶原羧基末端肽同分异构体( CTX)、碱性磷酸酶( ALP)、骨钙素、游离三碘甲状腺原氨酸( FT3)、游离甲状腺素( FT4)水平及 FT3/FT4升高，胃生长激素释放素( ghrelin)、 nesfatin-1、促甲状腺激素( TSH)、甘油三酯( TG)、总胆固醇( TC)、低密度脂蛋白胆固醇( LDL-C)水平降低( P<0.05)。治疗后，复方组血清 IGF-1、 IGFBP3、HDL-C、CTX、ALP、骨钙素、 FT3、FT4水平及 FT3/FT4高于 rhGH组， ghrelin、nesfatin-1［( 42.14±4.26)μg/L比( 44.72±4.53)μg/L］、 TSH、TG、TC、LDL-C、FPG水平低于 rhGH组(P<0.05)。复方组和 rhGH组不良反应总发生率比较差异无统计学意义(P>0.05)。结论赖氨肌醇维生素 B12对 ISS病儿具有一定效果，能提高 rhGH治疗疗效，缩小骨龄年龄差，降低血清 nesfatin-1水平，改善生长因子及骨形成指标，促进病儿生长，且安全性高。 |
| 英文摘要: |
| Objective To investigate the effects of lysine, inositol and vitamin B12 on the difference between bone age and chronologi. cal age and serum nesfatin-1 level in children with idiopathic short stature (ISS).Methods From February 2021 to June 2022, 95 chil.dren with ISS admitted to the Affiliated Hospital of Hebei University were selected as the study subjects and divided into a compoundgroup (48 cases) and a recombinant human growth hormone (rhGH) group (47 cases) using a random number table method. The rhGHgroup was treated with rhGH, while the compound group was treated with lysine, inositol and vitamin B12 oral solution in addition. The difference between bone age and chronological age, serum levels of related growth factors, and the incidence of adverse reactions werecompared between the two groups.Results After treatment, height, growth rate, and bone age in both groups were higher than beforetreatment, and the difference between bone age and chronological age was lower than that before treatment (P<0.05). After treatment,compared with the rhGH group, the compound group showed increases in height, growth rate, and bone age, and a decrease in the differ.ence between bone age and chronological age [(0.07±0.02) years vs. (0.45±0.11) years] (P<0.05). Compared with before treatment, se. rum levels of insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP3), high-density lipoprotein cho. lesterol (HDL-C), fasting plasma glucose (FPG), C-terminal telopeptide of type I collagen (CTX), alkaline phosphatase (ALP), osteocal.cin, free triiodothyronine (FT3), free thyroxine (FT4), and the FT3/FT4 ratio in both groups increased after treatment, while levels ofghrelin, nesfatin-1, thyroid-stimulating hormone (TSH), triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) decreased (P<0.05). After treatment, serum levels of IGF-1, IGFBP3, HDL-C, CTX, ALP, Osteocalcin, FT3, FT4, and the FT3/ FT4 ratio in the compound group were higher than those in the rhGH group, while levels of ghrelin, nesfatin-1[(42.14±4.26) μg/L vs. (44.72±4.53) μg/L], TSH, TG, TC, LDL-C, and FPG in the rhGH group were lower than those in the rhGH group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the compound group and the rhGH group (P>0.05).Conclu. sions Lysine, inositol and vitamin B12 have a certain therapeutic effect on children with ISS. They can enhance the therapeutic effectof rhGH, reduce the difference between bone age and chronological age, lower serum levels of nesfatin-1, improve growth factors and bone formation indicators, promote child growth, and have a favorable safety profile. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
